Zydus Lifesciences Limited and Dr. Reddy's Laboratories Ltd. announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India.
Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC). Under the terms of this agreement, Dr. Reddy's will receive semi-exclusive rights from Zydus to co-market the product in India. The product will be marketed by Zydus under the brand name SigrimaTM. Dr. Reddy's will market it under the brand name Womab®. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.